Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 diabetes. The decision comes after an international clinical trial found the risk of deteriorating kidney function was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. Katherine Ward has this story and more in Health Matters for Tuesday Aug. 19, 2025.
Health Matters
Health Matters: Health Canada approves Ozempic to help reduce kidney decline
More Videos
-
Health Matters: Crown Royal whisky recalled due to possible glass in bottles
-
Health Matters: Canada has highest number of measles cases in North America
-
Health Matters: What to know about the summer COVID-19 variant ‘Stratus’
-
Health Matters: Unlicensed Mitolux UV sunlamps may pose health risks, Health Canada says
-
Health Matters: Parts of Eastern Canada expected to see heat relief
You are viewing an Accelerated Mobile Webpage.
View Original Article